Elrig

APRIL 29, 2024

Srinivasan has led the development of multiple computational pipelines to process data from different next generation sequencing techniques with applications in oncology, genome editing systems including CRISPR-Cas mediated DNA editing, and ADAR-mediated RNA editing.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Agency IQ

JULY 21, 2023

The next chapter in the ctDNA story: Still promising, not ready for prime time A recent workshop summed up the state of play for circulating tumor DNA. But unlike ORR, PFS is considered by FDA to be a more appropriate measure of stable disease and is thought to be correlated to overall survival.

FDA 40

FDA Clinical Trials Treatment Trials 40

Agency IQ

FEBRUARY 2, 2024

The revisions flesh out considerations for use of biomarkers at all stages of product development and add new content on rare cancers and platform trial designs. after ischemic heart disease and stroke. In 2019 more than one in four (28%) of deaths in the E.U. were from cancer. Even under the shadow of the Covid-19 pandemic, 1.2

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40